Abstract: Microparticles are a heterogeneous population of small membrane-coated vesicles released by several cell lines upon activation or apoptosis. Microparticle generation seems to be a well regulated process, although these vesicles are highly variable in size, composition and function. Despite being previously considered inert debris without specific function, recent data demonstrated important pathophysiologic mechanisms orchestrated by microparticles in vascular diseases associated with endothelial dysfunction. These vesicles have been implicated, among others, in the pathogenesis of thrombosis, diabetes, inflammation, atherosclerosis and vascular cell proliferation. In addition to microparticles, circulating activated cells release smaller vesicles denominated exosomes that can also participate in vascular derangement. This mechanistic role of microparticles and exosomes in mediating vascular dysfunction indicates that they may represent novel pathways in short or long-distance paracrine transcelular signaling in vascular environment. The most recent patents regarding microparticles and exosomes are related to their procoagulant potential (U.S. Pat. No. 7005271), role in immune activation of T or B cells (Eurasian Pat. No. 0002827B1) and role in peptide vaccination (World Pat. No. 9705900A1). These commercial applications of microvesicles will be discussed in this review, as well as mechanisms involved in their origin, composition and participation in the pathogenesis of cardiovascular diseases.
INTRODUCTION
It is now well established that circulating cells in vascular environment as well as endothelial cells are capable of releasing membranous fragments (vesicles), of size varying from 100 nm to 1000 nm, bearing on their surfaces at least some of the antigenic markers of the parent cell (Fig. (1) ) [1] [2] [3] [4] [5] . The first description of these vesicles was reported in 1967, when Wolf et al [6] reported platelet membrane fragments in human plasma and called them "platelet dust". These vesicles were later called microparticles (or microvesicles) and the knowledge on its characterization and function has advanced since then, with increasing evidence for their role in transcelular communication in microvascular environment. However, the precise functions of these cell fragments and how they interact with cells in vasculature remain an unsolved issue.
Release of microparticles has been reported in several circumstances in normal physiology as well as in disease states. These vesicles have been implicated to play a role in inflammation, coagulation and diseases associated with impairment of vascular function, e.g. atherosclerosis, diabetes and hypertension [7] [8] [9] [10] . Usually, microparticle release is the result of cell activation or apoptosis, although it is not known whether cell activation and apoptosis lead to the formation of similar microparticles, in terms of size, lipid and protein composition and pathophysiological effects. Microvesicle release is an integral part of the membraneremodeling process in which the asymmetric distribution of constitutive phospholipids between the two leaflets is lost, with released microparticles exposing phosphatidylserine in the outer membrane, which acts as a template for the prothrombinase complex assembly and for their role in coagulation activation [11] .
The purpose of the present review is to summarize recent data on microparticle origin, composition and mechanistic role in inflammation, thrombosis and vascular dysfunction. The main commercial applications of microparticles regarding vascular diseases will also be discussed, as well as possible therapeutic strategies targeting microparticles in cardiovascular disorders. Relevant articles in this review were retrieved from a MEDLINE/PubMed search from 1966 to September 2006 on terms "microparticles", "microvesicles" and "exosomes". References from relevant articles were cross-referenced with additional original articles and review articles. A similar search was performed on Delphion system in order to obtain the most relevant patents regarding the review theme.
ORIGIN OF MICROPARTICLES
It is important to note, in first place, that circulating microparticles are a population of vesicles from different cell types and from different cellular compartment origins. As already discussed, the most common mechanism of microparticle release is cell activation or apoptosis, which induces plasma membrane budding, leading to the formation of membrane blebs [12] . However, apoptosis can also induce the formation of apoptotic bodies, which are sometimes considered as members of microparticles' family. Apoptotic bodies are cell fragments many times larger in diameter and volume than microparticles that are consequence of cell fragmentation in the final stages of apoptosis, in contrast with microparticles, that are released in the early moments of programmed cell death [13] . These apoptotic bodies also expose phosphatidylserine in the outer membrane, but unlike microparticles, have poor prothrombotic properties. Probably, the role of phosphatidylserine in these corpuscles is to recruit phagocytic cells to the site of apoptotic death [14] .
Other type of vesicle released after cell activation that can sometimes overlap microparticle function is the exosome. Unlike microparticles that are fragments of cell membranes, exosomes are preformed vesicles produced in the endocytic-lysosomal system of several cell lines. Exosomes diverge from microparticles in size (usually less than 0.1 µm), surface antigens and clotting capacity [14, 15] . The role of exosomes in cardiovascular diseases and sepsis is discussed in more details below.
Ectosome is another term used to characterize vesicles released from cell membranes. Most microparticles released from monocytes, neutrophils and platelets correspond to the definition of ectosomes. There is evidence for a structural and functional similarity between microparticles and ectosomes [5] . Given the considerations described above, it is important to note that usually in studies with micro-particles, preparations can in fact contain a mixture of different particle types with specific surface antigens and different roles in transcelular communication.
Virtually all cell types subjected to activation can release microparticles after blebbing of plasma membrane. The most common cell types associated with microparticle release as well as their cellular or vascular function are summarized in Table 1 . Besides such cellular sources, several other cell lines like erythrocytes, epithelial cells and tumor cell lines are capable of producing microparticles [5, [47] [48] [49] .
Their ubiquity has suggested a more general role for microparticles in cellular regulation, possibly with functions reminiscent of their original cell.
COMPOSITION OF MICROPARTICLES
The membrane of microparticles, which is derived from the parental cell plasma membrane, consists primarily of lipids and proteins, in variable amounts. The precise content of lipids and proteins is dependent on the cell they originate from and the type of stimulus involved in their formation [12] .
Microparticles are surrounded by a phospholipid bilayer. During the budding process, the normal phospholipid asymmetry of the membrane is lost, with microparticles exposing negatively charged phospholipids such as phosphatidylserine (PS) and phosphatidylethanolamine (PE) in their outer membrane leaflet. Exposure of PS plays a role in the in vivo effects of microparticles, since PS is an efficient site for coagulation factor activation. Analysis of components of microparticles from blood of healthy donors indicates that phosphatidylcholine represents more than 60% of their lipid content [50] . Other lipids present in minor concentrations are sphingomyelin, PS and PE. Although these microparticles are in the vast majority derived from platelets (~75%), their phospholipid composition is different from parental cell [2] .
Microparticles released in inflammatory environments can also have different lipid compositions when compared with microparticles of vascular milieu. For instance, microparticles obtained from synovial fluid of patients with inflammatory arthritis display almost equal amounts of PE, sphingomyelin, phosphatidylcholine and lysolipids and only small amounts of PS [51] . Another difference in lipid composition may be related to the oxidation status of lipids, since it is already reported that endothelial cells when exposed to oxidative stress release microparticles with oxidized phospholipids. These phospholipids were, however, virtually absent in microparticles from endothelial cells stimulated with calcium ionophore [18] .
Protein composition in the surface of microparticles is dependent of parental cell type. These surface antigens are specific for the cell they originate from and can help to identify the origin of microparticle. However, microparticle can differ in the expression of cell surface molecules from their parental cells. This is particularly important when microparticles express molecules upregulated or translocated by cell activation or apoptosis. For example, IL-1 alphaactivated cultured endothelial cells can release microparticles displaying E-selectin and endothelial cell adhesion molecule 1 in significantly higher concentrations than resting cultivated endothelial cells [52] . There is also data depicting different protein composition of microparticles in response to different agonists and with the same parental cell stimulated with the same agonist [53, 54] . Taken together, these differences indicate that shedding seems to be a well-regulated process that originates unique microparticle characteristics depending on the cell source, stimulus, scenario and pathophysiological conditions.
MECHANISMS OF MICROPARTICLE RELEASE
Platelets release microparticles after activation by thrombin, ADP plus collagen, calcium ionophore A23187 and high shear stress. Endothelial cells, monocytes and vascular smooth cells can release microparticles after activation by bacterial lipopolysaccharide, inflammatory cytokines, complement complex C5b-9 or reactive oxygen species [12] .
The mechanisms governing plasma membrane shedding and consequent microparticle release are only partially understood (Fig. (2) ). Usually, the shedding starts within minutes after addition of an agonist [55, 56] , by a calciumdependent process that can be blocked by calcium chelators. One of the possible molecules governing this process is calpain µ, which is a calcium-dependent cytosolic-protease that cleaves talin and α-actin. Inhibition of calpain by calpeptin or calcium chelators prevented the release of microparticles [2] . However, molecules other than calpain may be involved in calcium-dependent microparticles release, since blockade by calpeptin did not induce an inhibition of microparticle release to the same extent as EGTA, suggesting a role for other calcium dependent processes [57] . Cytosolic calcium increase may also activate kinases and inhibit phosphatases, which together with calpain activation, [25]
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-Upregulation of iNOS and cyclooxygenase-2 expression in vascular wall [45] [41] [46] are responsible for cytoskeleton disruption. Membrane skeleton disruption is the result of several mechanisms, such as myosin light-chain phosphorylation mediated by myosin light-chain kinase (MLCK) upon activation or Rhoassociated kinase I (ROCK-I), in apoptosis. Phosphorilation of myosin light chains (MLC) stimulates the contractile activity of myosin, with myosin ATPase activation creating movement between actin and myosin filaments. This movement may tensionate plasma membrane and cause detachment of the cytoskeleton from the membrane, with the formation of blebs and the subsequent release of microparticles. However, the precise interaction between cell membrane and cytoskeleton, which permits microparticle formation, is still unknown. Recent data has implicated ROCK-II (an isoform of ROCK-I) in thrombin-induced microparticle release from endothelial cells [58] . These new data recently incorporated indicates that the knowledge on mechanisms inducing cytoskeleton rearrangement during bleb formation is still scarce.
Another important feature in microparticle formation is the loss of phospholipid asymmetry of membranes after cell activation. Usually, PS and PE are specifically segregated in the inner leaflet, whereas phosphatidylcholine and sphingomyelin are enriched in the external one. This distribution is controlled by three enzymes: an inward-directed pump, a flippase (aminophospholipid translocase), specific for PS and PE; an outward-directed pump referred to as "floppase"; and a lipid scramblase, promoting unspecific bidirectional redistribution across the bilayer [59] . The increase in calcium content after cell activation may lead to collapse of the membrane asymmetry by stimulating scramblase and floppase activities and concomitantly inhibiting the flippase [4] . The increase in PS exposure in the outer leaflet that follows microparticle formation enhances coagulative properties and facilitates removal of apoptotic bodies by phagocytic cells. PS also binds annexin-5, which has been used in several studies for microparticle quantification [60, 61] .
Cellular plasmatic membranes also exhibit lipid microdomains, named rafts, which are responsible for lateral mobility of proteins and for recruiting signaling molecules [3, 61] . Lipid rafts are dynamic assemblies of sphingolipids and cholesterol whose integrity is essential for PS transverse redistribution in megakaryocytic HEL cells [62] . One recent study demonstrated that TF-containing microvesicles from monocytes arise from lipid rafts, since their shedding was significantly reduced by membrane cholesterol depletion [63, 64] . However, the exact mechanism of interaction between rafts and cytoskeleton is not known.
MICROPARTICLES IN INFLAMMATION
There is now emerging evidence that microparticles participate actively in regulation of vascular function in several healthy and disease states, as summarized in Table 2 . Microparticles, regardless their cell origin, can transfer biological information between cells, acting as veritable vectors of signaling molecules. Most of the exchange of information from microparticles takes place at the level of endothelium and contributes to their (patho)physiological role [1] . They have been reported to be part of the disease mechanisms in several conditions, such as inflammation, thrombosis and vascular dysfunction. Since these three elements are reported to be involved in the pathogenesis of cardiovascular diseases, role of microparticles in these processes will be discussed in detail. Although it is known that these conditions are highly interconnected, we separate them in this discussion for clarity.
It is now demonstrated from in vitro and in vivo studies that microparticles may play a role in inflammatory conditions, since they display a variety of proinflammatory activities. As already described in Table 1 , microparticles from endothelial cells, platelets and leukocytes can promote adhesion and rolling of leukocytes, contain proinflammatory cytokines and trigger the release of microparticles from several cell types in vitro [5, 18, 23, 24, 32, 33] . Additional evidence comes from reports of increased numbers of microparticles in inflammatory conditions in vivo [65, 66, 91] .
Microparticles can trigger inflammation by activating the complement cascade. Apoptotic Jurkat cells release microparticles that activate classical complement pathway, as demonstrated by deposition of C3 and C4 on the surface of microparticles [92] . The deposition of these early components of classical complement pathway could trigger their typical proinflammatory effects with additional vascular injury. Cardiopulmonary bypass multiple sources [75] Lupus anticoagulant endothelial [76] Congestive heart failure endothelial [77] Metabolic syndrome endothelial, tissue factor (+) [78, 79] Hypertension endothelial, monocyte, platelets [10, 80] Paroxysmal nocturnal hemoglobinuria platelet, endothelial [81, 82] Thrombotic thrombocytopenic purpura Platelet, endothelial [83, 84] End-stage renal disease endothelial [85] Sickle cell disease multiple source [86] Pulmonary and venous embolism platelet, endothelial [87, 88] Acute ischemic stroke endothelial [89] Arteriosclerosis obliterans platelet [90] Besides complement activation, another important feature of inflammatory conditions is leukocyte chemotaxis, adhesion and interaction with endothelium. Adhesion of monocytes and neutrophils to the endothelium is an early event in vascular inflammatory syndromes and a crucial step in the development of atherosclerosis [93] . Microparticles have been described as playing a crucial role in this phenomenon, since oxidized phospholipids from endothelial microparticles released by oxidative stress may cause monocyte adherence to endothelial cells and neutrophil activation [18] . Oxidative stress is a major contributor to apoptosis, an event closely related to many cardiovascular disease states, such as cardiomyopathy, myocardial infarction and atherosclerosis [94] . Oxidized phospholipids in lowdensity lipoproteins are also implicated in the pathogenesis of atherosclerosis. Taken together, the evidences depicted above suggest a role for microparticles in the pathogenesis of cardiovascular diseases.
Other microparticles released from different cell sources may have a role in mediating cellular interactions in vascular milieu. Platelet-derived microparticles, for instance, can enhance the binding of neutrophils to other neutrophils under flow conditions. This effect seems to be mediated by an interaction between P-selectin on microparticles and P-selectin-glycoprotein ligand 1 on neutrophils, since the blockade of these surface molecules can reduce this binding [23] . Microparticles derived from platelets can also stimulate monocyte-endothelial interactions, by delivering arachidonic acid to endothelial cells, which induces the upregulation of expression of cellular adhesion molecules (ICAM-1) on endothelium and CD11a/CD18 and CD11b/CD18 on monocytes [21] .
Platelet-derived microparticles, as well as vesicles from other cell lines, can contribute to inflammation by stimulating the production of several cytokines [28, 33, 41] . Microparticles derived from leukocytes can increase the production of IL-6, monocyte chemotactic protein 1 (MCP-1) and Tissue Factor (TF) in endothelial cells, in a pathway mediated by increased tyrosine phosphorylation of c-Jun NH(2)-terminal kinase (JNK1) [33] . Platelet-derived microparticles have been associated with increased production of IL-8, IL-1beta and TNF-alpha by a monocytic cell line (THP-1) and endothelial cells in high shear stress conditions [28] . In leukocytes, endotoxin stimulation induced the shedding of microvesicles containing platelet-activating factor (PAF), a known inducer of inflammatory response [37] .
Microparticles derived from lymphocytes and monocytes, in turn, are associated with stimulation of production of matrix metalloproteinases (MMP-1, MMP-3, MMP-9 and MMP-13) and cytokines (IL-6, IL-8, MCP-1 and MCP-2) by fibroblasts, as demonstrated in synovial cells [41] . In vascular medial layer, exposure to T-lymphocyte-derived microparticles induces upregulation of expression of inducible nitric oxide synthase and cyclooxygenase through NF-κB pathway [46] .
Evidence that microparticles participate in the genesis of inflammatory diseases is supported by studies that depicted increased number of microparticles in inflammatory conditions in vivo. Meningococcal sepsis, for instance, is associated with increased levels of microparticles released mainly from granulocytes and platelets [65] . These vesicles are highly procoagulant, which demonstrates the correlation among inflammation and coagulation in the pathogenesis of several vascular diseases. In patients with sepsis and multiple organ dysfunction syndrome, Joop et al. found increased number of microparticles released from granulocytes, and diminished levels of microparticles derived from platelets and erythrocytes were also found [66] . Trauma patients have also increased levels of leukocyte microparticles with enhanced expression of adhesion molecules on days 2 to 5 after injury [95] .
Besides sepsis and trauma, other diseases associated with inflammation are associated with elevated levels of circulating microparticles. Patients with HIV have increased levels of microparticles derived from T cells bearing CD4 antigen [96] . Plasma of children with active systemic vasculitis contained significantly higher numbers of Eselectin-positive endothelial microparticles, which correlated with activity score of the disease and acute-phase reactant levels [91] . Platelet-derived microparticles were also found to be elevated in plasma of patients with inflammatory bowel disease [97] . Data from in vitro experiments, strengthened by the studies that showed microparticle effects in vivo support the notion that these circulating vesicles are related to vascular inflammation in several disease states.
MICROPARTICLES IN VASCULAR DYSFUNCTION
Cardiovascular diseases have been associated with diminished vascular function, remarkably endothelial dysfunction. Many studies have isolated microparticles from blood of patients with disease states marked by vascular dysfunction, and these vesicles were associated with impairment of vascular function in isolated arteries [7, 8, 39, 45, 46] . Microparticles released from T-lymphocytes are capable of impairing endothelial function after 12 or 24 hours of incubation, also decreasing eNOS expression and increasing caveolin-1 expression of endothelial cells in culture [45] . Another investigation from the same group reported impairment of vascular function with microparticles released from an apoptotic T cell line in a mechanism associated with transcription factor NF-κB production and proinflammatory protein upregulation [46] . Microparticles from apoptotic lymphocytes of diabetic patients induce similar vascular hiporeactivity, therefore demonstrating a correlation between in vitro data and pathophysiological situations [46] . When originated from endothelial cells in culture, microparticles produce and induce superoxide production by aortic rings associated with impairment of acethylcoline-induced vasorelaxation [7] . These microvesicles also inhibit NO production by aortic rings and display p22(phox), a subunit of superoxide-producing enzyme NADPH oxidase, thus demonstrating an important role for oxidative stress in vascular dysfunction [7] . Another study demonstrated the ability of platelet microparticles to stimulate arachidonic acid-induced contractions in rabbit pulmonary artery rings, an effect inhibited by thromboxane receptor antagonists [26] . These data emphasize the role of microparticles in acting as a source of thromboxane A 2 and thus regulate vascular tone [1, 26] . In women with preeclampsia, although the total number of circulating microparticles was unaltered, the proportion of microparticles derived from lymphocytes and granulocytes was increased, and these vesicles were associated with impairment of endothelium-dependent relaxation [67] . However, there is still a lot to be discovered on the mechanisms of microparticles induced endothelial dysfunction. Indeed, a new approach in this regard is the evaluation of microparticles release after high-fat meals. An increase in the count of postprandial endothelial microparticles has been reported after a diet with enriched fat content [98] . Another study correlated two high-fat meals with enhanced microparticle production and impairment of endothelium-dependent vasodilation [99] . Thus, probably in vivo, the interaction of microparticles with molecules such as oxidized low-density lipoprotein may be partially responsible for vascular dysfunction in pathologic conditions.
MICROPARTICLES IN THROMBOSIS
The most known characteristic of microparticles is their ability to induce coagulation activation with subsequent thrombosis of vascular beds. There is substantial in vitro evidence of the involvement of microparticles in activation of coagulation system [18, 25, 78] . In vivo studies depicting increased concentrations of microparticles in diseases associated with coagulation activation corroborate the in vitro data [47, 53, 65] .
Circulating microparticles provide an additional procoagulant phospholipid surface for the assembly of the clotting enzymes complexes that promote thrombin generation. The assembly of vitamin-K dependent tenase and prothrombinase complexes in microparticles is known as platelet factor 3 activity. Platelet microparticles also display activated factor V in their surface, which may contribute to activation of clotting [61] . Endothelial microparticles, in turn, released after stimulation of endothelial cells in culture with plasminogen activator inhibitor-1 (PAI-1) become procoagulant with an accelerated thrombin production [100] . This activation of coagulation that occurs after microparticle release culminates with the generation of thrombin, which consequently induces hemostasis or a prothrombotic state. The stimulation of clotting that follows microparticle release requires a tight control exerted by natural anticoagulant systems. Indeed, binding of protein S to microparticle surface has already been described, with subsequent binding of protein C and activated protein C. The binding of protein C is regulated by a ~10-fold increase in PS concentration in the outer leaflet of the membrane [101, 102] .
A more direct mechanism relating microparticles and initiation of coagulation was described when TF was reported to be present in the surface of platelet-derived microvesicles [25] . TF has also been described in microparticles derived from monocytes [4, 103] and smooth muscle cells after apoptosis [40] . These cell lines are the vessel-wall providers of microparticles containing TF released into the blood stream following atherothrombotic plaque disruption [104] . Moreover, microparticles are capable of inducing TF expression on monocytes [105] . Since TF mRNA has not been demonstrated in megakaryocytes, platelet-derived and microparticles-derived TF is likely to originate from other cell lines, incorporated in platelets by transcelular exchange [103] . Activated monocytes could be a circulating source of TF acquired by platelets through CD-15 and TF-dependent interactions [35] . Regardless the origin, microparticle-associated TF triggers factor VII-mediated thrombin generation [106] . Tissue factor production in microparticles has also been associated with inflammatory conditions such as meningococcal disease [65] , thus demonstrating the continuous interplay between inflammation, coagulation activation and vascular thrombosis.
In addition to the direct effects of microparticles on coagulation system, they may also promote coagulation by indirect pathways. One of these mechanisms is the induction of expression of tissue factor in monocytes by P-selectin, a molecule that is often present on the surface of platelet microparticles [106] . This molecule is involved in leukocyte rolling and is upregulated during venous thrombosis, promoting vascular wall inflammation [102] . There is also reported correlation between platelet-derived P-selectin and microparticle recruitment through interactions between TFbearing microparticles and P-selectin ligand [43] . Thus, microparticles can activate coagulation and vascular inflammation through TF exposition and interactions between platelets and inflammatory cells in atherosclerotic plaques.
The evidence for microparticle contribution to coagulation in vivo is circumstantial. There are reports of increase in microparticle numbers in several diseases associated with hypercoagulation such as heparin induced thrombocytopenia [53] and acute coronary syndromes [70, 71] . Moreover, several diseases related with hypercoagulation are associated with production of microparticles exposing TF, such as disseminated intravascular coagulation [65] and pericardial wound blood [75] . The importance of the procoagulant role of microparticles has also already been demonstrated in patients with acute coronary syndromes [70] and metabolic syndrome of diabetes mellitus type 2 [78] , thus demonstrating a probable role of microparticles as contributors of atherosclerosis and vascular dysfunction in cardiovascular diseases.
The increasing recognition of the role of procoagulant microparticles in the pathogenesis of cardiovascular diseases has called attention to the development of assays to detect the prethrombotic state of an individual by measuring microparticles. In this regard, a recent method was developed to detect microparticles presence in the plasma of high-risk individuals by detecting the interaction of common microparticle compounds with anionic phospholipid antibodies or annexin-V [107] . This recent development may prove to be useful in detecting patients at risk of thrombotic events that could benefit from a more aggressive approach.
EXOSOMES ARE A SPECIAL TYPE OF MICROPARTICLES
Exosomes are frequently referred as a specialized category of microparticles with specific functions in immune response and protein sorting. They are released mainly from antigen presenting cells [108, 109] , although exosomes have been identified after platelet [110, 111] and mast cell [112] activation and in body fluids, such as urine [113] or bronchoalveolar lavage [114] . Dissimilar to microparticles, exosomes are more homogeneous in size (diameters ranging from 60 to 100 nm) and composition, and are enriched in tetraspaning proteins [115, 116] . They are also derived from endocytic-lisosomal cellular system, whereas microparticles are fragments of plasmatic membrane. Platelet-derived exosomes display PS in a much less extent than microparticles, thus they are poor coagulation activators [111] . However, they exhibit major histocompatibility complex (MHC) class I or II molecules in their surface, which demonstrate their role in antigen presentation [112, 117] . Common filtration and centrifugation processes used to separate microparticles frequently cannot eliminate these small particles. Thus, some of the biologic effects of microparticles observed in the literature may be due to the presence of exosomes in the preparation.
The most common clinical application of exosomes is related to their role in antigen presentation and immune stimulation. Exosomes derived from dendritic cells have been used to stimulate T -lymphocytes to produce specific antigens associated with tumor rejection [118, 119] . The ability of exosomes to induce responses to eradication of tumors has been tested in some preliminary clinical trials where these vesicles were used in patients with melanoma with encouraging results [116] . The most recent patents described in this field are related to the production and separation of exosomes [119] , their role in peptide vaccination [108] , possible immunosuppressive effect [109] , and use in immune stimulation of T or B cells [115] . At the present time, there are no patents of exosomes regarding their effect in vascular function.
The role of exosomes in vascular diseases remains deeply unexplored. One study from our laboratory identified in septic patients' plasma exosomes derived predominantly from platelets. These vesicles have been associated with vascular dysfunction of sepsis, due to their effects in inducing apoptosis of endothelial cells and vascular smooth muscle cells in culture, in a mechanism mediated by oxidative stress [14, 120] . They display components of NAD(P)H oxidase in their membrane and are capable of production of reactive oxygen species per se [14] . We have demonstrated also that these vesicles induce cardiac dysfunction, in a mechanism probably related to NO production (Azevedo et al, unpublished data) . Thus, in a condition associated with severe vascular dysfunction such as sepsis, exosomes may play a role in regulating vascular function and regulation of transcelular influx of proteins and antigens in vascular compartment. In another study, mast cells-derived exosomes induce endothelial cells to secrete plasminogen activator inhibitor type 1, thus demonstrating a possible role of exosomes in the relationship between thrombosis and vascular dysfunction [121] . However, the contribution of exosomes to vascular derangements in pathologic conditions remains open.
MICROPARTICLES AS THERAPEUTIC TARGETS
The understanding of the precise role of microparticles in cardiovascular dysfunction may be useful not only to increase our knowledge on the pathogenesis of these diseases, but also may have implications for the treatment of these patients. In cardiovascular diseases, several drugs may influence the release of microparticles and this mechanism could account for the beneficial effect of these pharmacological approaches. For instance, a platelet GPIIb-IIIa receptor antagonist (abciximab), an antiplatelet drug used after percutaneous coronary intervention has been associated with the reduction in microparticle release by platelets at high shear stress [122] . This molecule has also been related to reduction in microparticles counts after coronary angioplasty and to prevention of vascular dysfunction mediated by microparticles released from apoptotic vascular smooth muscle cells [39, 123, 124] . The prevention of vascular dysfunction was also reported with eptifibatide, another beta3-integrin antagonist, which also prevented microparticle-induced inhibition of NO production by cultured endothelial cells [39] .
In addition to integrin antagonists, statins are other class of drugs already reported to reduce circulating microparticles levels [125] [126] [127] . A combination of losartan and simvastatin reduced circulating monocyte-derived microparticles in hypertensive patients, in a larger extent than anti-hypertensive therapy alone [125] . Statins also reduced GPIIIa antigen in platelet microparticles from diabetic patients and endothelial microparticle release in TNF-alpha stimulated cells in culture [126, 127] .
Since several pathways are associated with microparticle release, the blockade of these shedding promoters may reduce microparticle levels and become alternatives to pharmacological approaches. Indeed, the supression of mechanisms such as oxidative stress and neurohormonal stimulation (angiotensin II) has already been associated with diminished levels of circulating microparticles [77, 128, 129] . Whether the reduction of microparticles release associated with pharmacological interventions is associated with clinical improvement remains to be proven.
CLINICAL APPLICATIONS OF MICROPARTICLES MEASUREMENT
As already described in the text, the most compelling evidence of microparticle role in clinical scenario is circumstantial. Thus, an increase in microparticle measurement in clinical practice may indicate an enhancement in cell injury, stress, thrombosis or inflammation. So far, the only clear clinical application of microparticle measurement is related to their procoagulant potential, since increased concentrations of microparticles may represent platelet activation. Measurements of quantitative or functional assays of platelet microparticles may be useful to detect patients with high risk of thrombotic events that could be treated with pharmacological interventions associated with microparticle inhibition, such as abciximab or statins [124, 125] .
Data regarding prognostic value of measurement of circulating levels of microparticles are preliminary. In acute coronary syndromes, the presence of circulating particles containing annexin V has been strongly correlated to occurrence of secondary myocardial infarction or death. In asymptomatic subjects, circulating leukocyte-derived microparticles predict subclinical atherosclerosis as evaluated by plaque numbers in several vascular sites [12] . However, additional confirmatory studies are necessary.
CURRENT & FUTURE DEVELOPMENTS
In this review we have assessed the current knowledge on microparticle formation, composition and function, as well as their role in vascular dysfunction. So far, accumulating data suggests that microvesicles play a role in inflammation, thrombosis and vascular dysfunction, three processes that are involved in the pathogenesis of cardiovascular diseases. Additional studies are necessary to delineate more precisely the pathways involved in microparticle regulation of vascular function. Clarification of their composition as well as the underlying mechanisms involved in their effects will help us to develop additional interventional strategies for prevention and treatment of cardiovascular diseases.
